GENINUS, Inc.
KKRX:3890301,416.00
KRW
-27.00
(-1.87%)
ISIN
KR7389030008
Return %
Stock
S&P 500
1Y
-35.49
14.39
3Y
-56.89
81.42
5Y
- -
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Woong-Yang Park
- Full Time Employees
- 59
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Seoul South Korea
- IPO Date
- Nov 8, 2021
- Website
- geninustx.com
- Similar Companies
- Business
- GENINUS, Inc. is a South Korea-based biotechnology and precision medicine company that develops and commercializes genomic analysis solutions, single-cell multiomics platforms, and artificial intelligence-driven drug discovery technologies. Founded in 2018 as a spin-off from the Samsung Genome Institute at Samsung Medical Center and headquartered in Seoul, South Korea, the company serves clinical hospitals, research institutes, and biopharmaceutical companies across South Korea, Japan, and international markets. GENINUS, Inc. operates through comprehensive diagnostic and translational research business segments, offering a systematic product and service portfolio that includes CancerSCAN, a next-generation sequencing panel for solid tumor genomic mutation profiling and targeted therapy selection; LiquidSCAN, a non-invasive cell-free DNA liquid biopsy assay for cancer monitoring and minimal residual disease detection; HealthSCAN, a preventive genomic screening service; Celinus, an ultra-high-resolution single-cell multiomics sequencing and spatial biology analysis service; OncoSTATION, a bioinformatics clinical reporting and interpretation platform; and CASOD, a proprietary clinical-genomic database. In addition, the company provides computational discovery solutions, including IntelliMed, an AI-powered multiomics analysis platform for target and biomarker identification; and IntelliRVL, an in silico neoantigen prediction platform for personalized cancer vaccine and immunotherapy development. In recent developments, GENINUS, Inc. has executed a strategic shift toward a Platform-to-Asset business model, leveraging its AI and spatial omics technologies to discover proprietary therapeutic candidates, such as antibody-drug conjugates, bispecific antibodies, and neoantigen cancer vaccines. The company has expanded its global presence through its Japanese subsidiary, GxD Inc., securing multiomics and AI drug discovery collaboration contracts with major Japanese pharmaceutical corporations. Additionally, GENINUS, Inc. has established commercial platform partnerships with domestic biopharmaceutical developers, including ABL Bio, and secured 20 billion South Korean won in convertible preferred share investment from institutional venture capital to accelerate therapeutic asset development and platform commercialization.